Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUARDIAN-1: Ganetespib + Chemoradiation for Esophageal Cancer
NCT02389751Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2015
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ganetespib in esophageal carcinoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 70 days. Started Apr 2015; status: completed.
02
Drugs
ganetespib
03
Conditions
esophageal carcinoma
Beyond the preview
Go deeper on NCT02389751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02389751.